Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Information on the total number of voting rights and shares
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation
Nyxoah S.A. (NASDAQ: NYXH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock, up previously from $18.00.
Nyxoah S.A. (NASDAQ: NYXH) had its price target raised by analysts at Stifel Nicolaus from $20.00 to $27.00. They now have a "buy" rating on the stock.